TISSUE BIOLOGY · FUNCTIONAL EVIDENCE
These studies establish that ASH1L can have lineage- and state-specific functions. Species, perturbation direction, developmental timing, and cell identity determine what each experiment can support.
DIRECT FUNCTIONAL EVIDENCE
The reviewed experiments show what ASH1L can regulate in defined models. They do not demonstrate that the same function is altered by an individual germline allele in the corresponding human tissue.
OPEN GAP
A patient-allele claim requires measurement in a relevant human cell state, an appropriate comparator, and rescue of the measured effect.
Scroll horizontally to review every column.
| System and model | Direct result | Limit | Source |
|---|---|---|---|
| Human neural cell stateshiPSC-derived neural progenitors; immature and mature glutamatergic neurons; mature GABAergic neurons · Human cell model | Pooled CRISPR knockout showed that ASH1L-associated transcriptional consequences depend on developmental stage and neuronal identity. | Complete knockout in engineered cells does not measure residual function from an individual patient variant. | Fernandez Garcia et al., 2026 ↗ |
| Developing brainNeural-progenitor deletion in mice · Direct in vivo | Ash1l loss altered cortical development, progenitor programs, myelination, growth, and later behavioral and memory measures in the tested model. | A neural-lineage mouse deletion does not establish cell autonomy in every brain lineage or reproduce the full human disorder. | Gao et al., 2021 ↗ |
| Prefrontal cortexRegion-specific Ash1l knockdown in mice · Direct in vivo | The perturbation altered promoter chromatin and synaptic-gene transcription, shifted excitation/inhibition balance, and produced seizure phenotypes. | A regional knockdown cannot define every cell type, variant architecture, or human seizure trajectory. | Qin et al., 2021 ↗ |
| Thalamocortical memory circuitTargeted CRISPR perturbation in a mouse memory task · Direct in vivo | ASH1L was required later in the tested cascade to maintain memories over weeks, while initial memory formation was preserved. | This is circuit- and task-specific evidence; it does not define a person’s memory profile or prove progressive decline. | Terceros et al., 2026 ↗ |
| Macrophage / innate immuneMacrophage and inflammatory mouse models · Direct lineage model | Ash1l promoted A20/Tnfaip3 expression and restrained TLR-triggered NF-κB/MAPK signaling and IL-6/TNF production in the tested models. | This does not establish immune deficiency, autoimmunity, or hidden inflammation in people with ASH1L-related disorder. | Xia et al., 2013 ↗ |
| CD4 T-cell differentiationMouse T-cell polarization with human rheumatoid-arthritis correlation · Direct lineage model | Ash1l and lnc-Smad3 oppositely regulated Smad3-locus accessibility and induced regulatory T-cell polarization. | The study concerns immune-lineage regulation and autoimmunity models, not ASH1L neurodevelopmental-disorder prevalence. | Xia et al., 2017 ↗ |
| Hematopoietic stem cellsConditional Ash1l deletion in mouse hematopoietic stem and progenitor cells · Direct lineage model | Ash1l supported adult stem-cell quiescence, long-term trilineage hematopoiesis, and Hox-gene expression in the tested system. | Stem-cell lineage biology does not establish blood-count abnormalities, immune deficiency, or leukemia risk in ASH1L-related disorder. | Jones et al., 2015 ↗ |
| Epidermis / keratinocytesHypomorphic Ash1l mouse skin · Direct tissue model | Ash1l disruption altered keratinocyte proliferation–differentiation balance, epidermal stratification, and wound re-epithelialization. | This supports a skin-homeostasis mechanism in mice; it does not establish a universal human skin phenotype. | Li et al., 2017 ↗ |
| Neuronal–cutaneous inflammatory axisAsh1l perturbation in a mouse psoriasis model · Cross-tissue model | Neuronal Ash1l altered activity-dependent let-7b release and downstream cutaneous inflammatory signaling in the tested disease model. | A psoriasis model does not establish psoriasis, neuroinflammation, or one shared skin mechanism in germline ASH1L haploinsufficiency. | Du et al., 2024 ↗ |
| Skeletal muscle / myoblastsMouse myoblasts, developing muscle, and regeneration models · Direct tissue model | Ash1l activated Cdon and supported myoblast fusion, a process required for muscle formation, growth, and repair. | The result does not establish a primary myopathy or explain every motor, tone, fatigue, or recovery finding. | Castiglioni et al., 2018 ↗ |
| Bone / osteoclast lineageMouse osteoclast differentiation and bone-loss models · Direct tissue model | ASH1L restrained osteoclastogenesis and bone resorption in the tested models. | Human bone fragility or osteoporosis is not established as an ASH1L-related-disorder mechanism. | Zhao et al., 2024 ↗ |
| Fetal ovary / oocytesAsh1l overexpression in mouse fetal ovaries · Dosage-context model | Excess Ash1l was associated with impaired DNA double-strand-break repair signaling and oocyte apoptosis in that model. | The perturbation is overexpression—the opposite direction from haploinsufficiency—and cannot be used to infer fertility risk. | Zhang et al., 2022 ↗ |
| Heart developmentDrosophila cardiac tissue · Distal in vivo model | Ash1 with Caf1-55 and MRG15 supported H3K36me2-dependent heart development in vivo. | A fly developmental result does not establish a human cardiac phenotype or clinical risk. | Zhu et al., 2023 ↗ |
TESTABLE STATE-RESOLUTION QUESTION
Experimental ASH1L studies address several different state processes: neural progenitor proliferation, hematopoietic quiescence, epidermal repair, inflammatory restraint, muscle differentiation, bone resorption, and memory stabilization. They do not establish one universal “failure to close.”
Glia and barrier epithelium are priority comparison models—not established primary targets and not an explanation assigned to an individual person.
Compare maturation, excitability, transmitter and ion handling, metabolic support, myelination, and recovery after a defined challenge.
Human expression supports model selection; completed patient-allele astrocyte evidence is not yet established.Compare barrier integrity, repair kinetics, fluid and ion transport, and local inflammatory shutoff in the relevant tissue context.
Mouse epidermal perturbation is direct evidence; oral, airway, and GI epithelium remain proposed human-relevant models.Measure baseline, challenge, peak, shutoff, recovery, and repeat challenge with isogenic controls.
Rescue must normalize the relevant molecular and functional readout, not only one downstream marker.OPEN
Measure stimulus threshold, onset latency, magnitude, cell identity, and the pathway initially engaged.
TRANSITION
Test differentiation, maturation, sleep–wake transition, network-state change, and tissue-specific adaptation.
CLOSE
Measure transcriptional shutoff, electrical recovery, inflammatory restraint, and the time required for a triggered program to end.
RESOLVE
Track recovery curves, residual state, recurrence threshold, tissue repair, and whether function stabilizes after the trigger is gone.